FIELD: medicine, pharmacy. SUBSTANCE: invention relates to preparations of ranolazine. The ranolazine preparation of prolonged effect contains uniform mixture of ranolazine and partially neutralized pH-dependent binding substance for a film formation that is insoluble in an aqueous medium usually at pH below 4.5 but it is soluble in an aqueous medium at pH above 4.5. Preparation is useful for administration of ralonazine, 2 times per a day, and can be used for maintaining ranolazine levels in human blood plasma between its concentration 350 and 7 500 ng/ml. Invention provides the development of medicinal form of prolonged effect and maintenance the preparation concentrations for at least 24 h. EFFECT: valuable medicinal and pharmaceutical properties of preparation. 20 cl, 9 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF TREATMENT OF CARDIOVASCULAR DISEASES | 1999 |
|
RU2207856C2 |
| METHOD OF DIABETES TREATMENT | 2007 |
|
RU2442585C2 |
| METHOD FOR TREATING DIABETES | 2003 |
|
RU2320343C2 |
| PROLONGED RELEASE PHARMACEUTICAL PREPARATIVE FORMS | 2006 |
|
RU2384332C2 |
| USE OF RANOLAZINE FOR PREPARATION OF MEDICINE FOR ARRHYTHMIA TREATMENT | 2003 |
|
RU2325161C2 |
| METHODS OF HEARTBEAT FREQUENCY REDUCTION INCLUDING ADMINISTRATION OF ADENOSINE A RECEPTOR AGONIST TOGETHER WITH BETA-BLOCKER, CALCIUM CANAL BLOCKER OR CARDIAC GLYCOSIDE | 2003 |
|
RU2332220C2 |
| PRODRUG OF ADENOSINE A RECEPTOR ANTAGONISTS | 2006 |
|
RU2415858C2 |
| DERIVATIVES OF HETEROARYLALKYLPIPERAZINE AND PHARMACEUTICAL COMPOSITION BASED ON THEREOF | 2001 |
|
RU2243970C1 |
| α-KETOAMIDE INHIBITORS OF 20S-PROTEASOME | 1999 |
|
RU2192429C2 |
| PURINE RIBOSIDES AS ANTI-ARRHYTHMIC AGENTS | 2001 |
|
RU2248208C2 |
